Immunomedics Announces Commercial Availability of TRODELVY™ in the United States
BY GlobeNewswire
— 8:00 AM ET 05/04/2020
MORRIS PLAINS, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. ( IMMU), (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Trodelvy (sacituzumab govitecan-hziy) is now available through major specialty distributors in the United States and that the first patient was treated with commercial product on April 29, 2020. Trodelvy is the first anti-Trop-2 ADC recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.
“We are excited to have Trodelvy rapidly available upon FDA approval, an important first step in our drive to gain brand awareness and adoption by healthcare providers,” said Brendan Delaney, Chief Commercial Officer of Immunomedics ( IMMU). “We want all eligible mTNBC patients, who have had at least two prior therapies, to have the opportunity to benefit from Trodelvy as a new treatment. In so doing, we hope to establish Immunomedics ( IMMU) as a trusted and differentiated partner within the breast cancer community.”
Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics ( IMMU), commented, “Today’s announcement marks an important milestone for Immunomedics ( IMMU) as we have, for the first time in the Company’s history, commercially launched a therapeutic product. Our continuing mission is to unlock the full potential of Trodelvy for the benefit of cancer patients worldwide.” |
